ValeurQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMFrais de vente, généraux et administratifs414.48 M374.09 M412.81 M414.37 M472.36 M421.91 M1.72 BRecherche et développement———————Résultat d'exploitation565.36 M438.94 M537.84 M505.77 M561.07 M481.89 M2.09 BTotal des produits hors exploitation-12.91 M-17.55 M-22.85 M-41.26 M-21.03 M4.47 M-80.67 MCharges d'intérêts, nettes des intérêts capitalisés———————Résultat hors exploitation, hors charges d'intérêts0000000Revenus/dépenses exceptionnels-12.91 M-17.55 M-22.85 M-41.26 M-21.03 M4.47 M-80.67 MRésultat avant impôts413.73 M286.33 M368.93 M308.8 M382.76 M341.23 M1.4 BPart des actionnaires dans le résultat10.31 M5.61 M7.36 M10.16 M9.87 M8.34 M35.73 MImpôts64.49 M54.12 M93.71 M68.55 M76.73 M66.2 M305.19 MIntérêts ne donnant pas le contrôle / intérêts minoritaires89.92 M69.3 M75.88 M89.92 M96.81 M77.5 M340.12 MAutres produits/charges après impôts10.74 M-7.14 M189 K-4.57 M29.07 M-6.71 M17.98 MRésultat net avant activités abandonnées259.33 M162.92 M199.34 M150.33 M234.22 M197.53 M781.42 MActivités abandonnées———————Résultat net259.33 M162.92 M199.34 M150.33 M234.22 M197.53 M781.42 MAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires259.33 M162.92 M199.34 M150.33 M234.22 M197.53 M781.42 MBénéfice par action de base (BPA de base)3.172.052.622.093.32.9310.94Bénéfice par action dilué (BPA dilué)3.0822.582.043.222.8710.71Nombre moyen d'actions de base en circulation84.99 M79.37 M75.94 M72.08 M74.23 M67.39 M—Nombre d'actions en circulation après dilution87.27 M81.28 M77.36 M73.77 M75.89 M68.88 M—EBITDA572.83 M———568.17 M——EBIT565.36 M438.94 M537.84 M505.77 M561.07 M481.89 M2.09 BCoût des ventes———————Autres coûts des ventes———————Amortissements (flux de trésorerie)7.46 M———7.1 M——
DaVita Inc. Common Stock
DaVita Inc., incorporated in Delaware and headquartered in Denver, provides kidney dialysis services through a network of 2,657 outpatient centers in the United States, serving 200,500 patients, and 585 outpatient centers in 14 other countries serving 94,500 patients. The company primarily treats end-stage renal disease, which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
In 2025, 68% of the company's revenues came from Medicare and other government-based health insurance programs. In 2025, 89% of the company's patients were covered by government-based health insurance programs. Commercial payers, which accounted for 32% of revenues in 2025, generate nearly all of the company's profit as they reimburse at a much higher rate than government-based health insurance programs.
The company is ranked 331st on the Fortune 500.